Atlantic Pharmaceuticals Ltd have now completed recruitment of pouchitis patients for a new treatment study.
Name of trial: Phase III Double-Blind Randomised Controlled Trial of Topical Alicaforsen Enema in Antiobiotic Refractory Pouchitis
Name of medicine/drug: Alicaforsen enema (240 mg) or placebo; self administered each night for up to six weeks.
Patient enrolment period: Closed
Location: Across the UK (and worldwide)
There is currently no licensed product approved for the treatment of acute flares of pouchitis, although the use of antibiotics has become accepted as the norm for many patients. Unfortunately, over a period of time the efficacy of antibiotics declines and patients may fail to respond – they become “refractory” to treatment. Alicaforsen enema is a new product being investigated for the treatment of “antibiotic refractory” pouchitis. This is a Phase III trial which means the product has already gone through rigorous testing. This aim of this study is to increase the numbers of patients testing the treatment and look at the potential benefits and side effects.
Patient recruitment for the study has now concluded, you can get in touch with Atlantic via the link below if you have any questions.
For further information on the study, and how to get involved, please visit: http://www.atlantichc.com/for-patients
This trial is not funded or organised by Crohn's & Colitis UK, and therefore we cannot take responsibility for your involvement in the research.